Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938456 | 0.90 | CYP1A2 (0.73) | CYP1A2SCN5AL3MBTL1TRPV3DGAT1 | |
| SCHEMBL936862 | 0.86 | CYP1A2 (1.00) | CYP1A2SCN5AL3MBTL1TRPV3NPSR1 | |
| SCHEMBL20203716 | 0.84 | CYP1A2 (0.78) | CYP1A2SCN5AL3MBTL1TRPV3NPSR1 | |
| SCHEMBL20203755 | 0.83 | CYP1A2 (0.84) | CYP1A2SCN5AL3MBTL1TRPV3NPSR1 | |
| SCHEMBL20203703 | 0.81 | CYP1A2 (0.50) | CYP1A2SCN5ADGAT1METKDM4E | |
| SCHEMBL20203715 | 0.80 | CYP1A2 (0.72) | CYP1A2SCN5AL3MBTL1TRPV3NPSR1 | |
| SCHEMBL20203854 | 0.80 | CYP1A2 (0.53) | CYP1A2SCN5AL3MBTL1TRPV3NPSR1 | |
| SCHEMBL937513 | 0.73 | CYP1A2 (0.70) | CYP1A2SCN5A | |
| SCHEMBL23522703 | 0.73 | CYP1A2 (0.68) | CYP1A2SCN5AL3MBTL1METKDM4E | |
| SCHEMBL20203740 | 0.73 | CYP1A2 (0.68) | CYP1A2SCN5AL3MBTL1METKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | claimed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| EP-2464645-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Palo Alto, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885L3MBTL1 1392/4885 |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | CYP1A2 1580/4885SCN5A 52/4885L3MBTL1 4229/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | CYP1A2 1580/4885SCN5A 52/4885L3MBTL1 4229/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885L3MBTL1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.